Citius Pharmaceuticals

+$0.0217 (+2.26%) Today
-$0.0118 (-1.20%) As of 12:00 AM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CTXR and other ETFs, options, and stocks.

About CTXR

Citius Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to people suffering from hemorrhoids, NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome, and I/ONTAK, a protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL).

CEO
Leonard L. Mazur
Employees
15
Headquarters
Cranford, New Jersey
Founded
2007

CTXR Key Statistics

Market cap
143.49M
Price-Earnings ratio
—
Dividend yield
—
Average volume
2.37M
High today
$1.01
Low today
$0.9195
Open price
$0.9301
Volume
934.46K
52 Week high
$3.70
52 Week low
$0.8306

CTXR Earnings

-$0.15
-$0.10
-$0.05
$0.00
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Estimated
— per share
Actual
Expected Aug 11, After Hours
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure